Tags: 
From the beginning, pharmaceutical companies engaged in the development of COVID-19 vaccine were aware that to defeat the pandemic they had to address proactively virus variants.
Moderna in a Nov. 2021 press release (https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Strategy-to-Address-Omicron-B.1.1.529-SARS-CoV-2-Variant/default.aspx) stated that a 100-µg booster dose of the Moderna approved COVID-19 vaccine is studied for protection against the Omicron variant. In addition, the company has designed three candidates to anticipate mutations such as these of the Omicron variant. According to the press release, the first candidate includes mutations present in the Omicron and Beta variants, and a second candidate includes mutations present in the Omicron, Beta and Delta variants. The last candidate is an Omicron-specific booster candidate. All these three candidates are developed in parallel.
Johnson & Johnson, in a Nov. 2021 statement (https://www.jnj.com/johnson-johnson-to-evaluate-its-covid-19-vaccine-against-new-omicron-covid-19-variant) said that the immune response of its COVID-19 vaccine against variants is in clinical studies. The company COVID-19 team is conducting real world effectiveness studies ongoing in South Africa to generate new data on Omicron.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.